Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221 (GEROPHARM LLC, Russia) and Ozempic®.

PHASE1CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

May 5, 2024

Study Completion Date

May 5, 2024

Conditions

PharmacokineticsSafety IssuesBioequivalence

Interventions

DRUG

GP40221

Solution for Subcutaneous Administration 1.34 mg/ml

DRUG

ozempic

Solution for Subcutaneous Administration 1.34 mg/ml

Trial Locations (1)

Yarosslavl Clinical Hospital #3, Yaroslavl